Traws Pharma, Inc.

Healthcare · Biotechnology · United States

Last price 0.301 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.63M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib...